Eli Lilly Launches Multi-Dose Zepbound KwikPen to Boost GLP-1 Patient Retention
Eli Lilly has launched a multi-dose Zepbound KwikPen with four weekly doses in one device, priced at $299 per month for self-pay patients via LillyDirect. The FDA-cleared pen aims to improve adherence, reduce friction, and streamline GLP-1 distribution.






